Under the agreement Endo will retain all rights to the molecules developed, while Syngene will receive research fees, milestone payments and success fees from Endo, the company said.
Through this partnership, Syngene International and Endo Pharmaceuticals hope to leverage their synergistic capabilities and innovate novel therapeutic molecules for a robust cancer pipeline.
Published 22 March 2010, 15:39 IST